Better Choice to develop weight loss supplement for pets
The Florida-based pet health and wellness firm recently acquired all issued and outstanding shares in Canadian Aimia Pet Healthco for an undisclosed amount.
Following this acquisition, Better Choice plans to enter the glucagon-like peptide 1 (GLP1) market, an ingredient targeted at preventing obesity and, therefore, illnesses associated with overweight pets.
The company will now be “in a position to manage the clinical trials internally in hopes to develop a supplement to support weight loss in domestic animals.”
Following Pfizer’s creation of its Slentrol medication, Better Choice will work with Aimia to develop treats and toppers to “safely combat” obesity in pets.
“The goal of the research and development work is to mirror the weight loss benefits of leading brands for domestic animals and in humans, including Slentrol, Wegovy, Ozempic and Mounjaro, with added protein and nutrients from the company’s Halo products to promote lean muscle and overall pet health,” a company spokesperson says.
Founded in 2019 and headquartered in Tampa, Florida, Better Choice offers a range of pet health and wellness products for dogs and cats under its supplement brand Halo.
The recent State of US Pet Obesity Report concluded that 61% of cats and 59% of dogs were classified as overweight or obese in 2022.
Share this story:
